aidsmap news story
A pair of immune-modulating drugs, budigalimab and trosunilimab, appeared to slow viral rebound in about a quarter of people with HIV who stopped antiretroviral therapy (ART), according to study results presented at CROI 2026. Some participants eventually saw their viral load rise with further follow-up, however, and development of this combination will not continue.
Based on presented results, “levels and durability of ART-free viral control are not sufficient to offer transformational benefits to people living with HIV and do not justify further development of budigalimab plus trosunilimab,” the researchers concluded. “These findings suggest that further studies of immune-mediated therapy with anti-PD1 agents may require approaches involving novel mechanisms.”
Read the full news story here.
View all aidsmap reports from CROI 2026
Source : aidsmap
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.